Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Phase 1b study of cyclophosphamide, pomalidomide, dexamethasone, and daratumumab (CPD-DARA) in relapsed/refractory multiple myeloma: Safety and efficacy in a heavily pretreated population

View Full Paper
Ask AI
Bookmark
Share

Authors

VMVitaliy MykytivMCMary R. CahillSBShikha Bakshi

Discussion

Loading...

Member takes

Overview

Phase 1b trial shows CPD-DARA improves progression free survival in relapsed multiple myeloma, indicating safety with common adverse events.

Key Points

  • To assess the safety and efficacy of CPD-DARA in patients with relapsed/refractory multiple myeloma.
  • Conducted a Phase 1b multi-centre trial
  • Patients received CPD-DARA and were monitored for dose limiting toxicities
  • Main endpoint was to determine the maximum tolerated dose of pom in the regimen.
  • Median progression free survival was 15 months in the cohort
  • Adverse events included neutropenia in 56% and lymphopenia in 50%
  • No dose limiting toxicities were reported, establishing the maximum tolerated dose of 4mg pom.

Cite This Study

Mykytiv et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da7fhttps://doi.org/10.1182/blood-2025-4031
View Full Paper
Ask AI
Bookmark
Share